The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 30, 2025 for Ravi Agrawal, trustee ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajanta Pharma has informed the exchanges about a disclosure received under Regulation 31(1) and 31(2) of the SEBI Takeover Regulations on June 30, 2025. The disclosure has been filed by Ravi Agrawal, who is acting in the capacity of a trustee, indicating it relates to the promoter/promoter group shareholding. Regulation 31 deals specifically with disclosures of encumbered (pledged) shares, suggesting an update on the pledge status of promoter-held shares. The full details of the disclosure, including the extent of encumbrance and any change in pledged shares, are not available in the provided excerpt.
For shareholders, this filing signals that there has been a change or confirmation in the pledge status of promoter group shares. Investors should watch for the detailed disclosure to understand if pledges have been created, released, or invoked, as material changes can affect stock price sentiment and promoter confidence in the company.